after Merck and Moderna hit both Phase 3 melanoma endpoints, MRNA rose 136% and MRK 10.4% with no direct HYPE bid. a TradeXYZ MRNA perp adds a HYPE bid only when fees fund HYPE buys and burns. under HIP-3, TradeXYZ posts one DEX stake, so a new market locks no extra 500k HYPE. ...

Merc is up by about 5.8%. Madna shares are up by 70% this morning. It's a gain of more than $43 to $107.3%.This comes on positive topline results from a large phase 3 trial of the two companies melanoma treatment. It combines individualized mRNA based therapy with Merc's Kitruda for patients who have had melanoma surgically removed. That trial did meet both its primary and secondary endpoints of survival without recurrence of the cancer as well as survival without the cancer spreading to other parts of the ...

Moderna Co-Founder Robert Langer Is A Billionaire Again As Shares Double In Valuehttps://t.co/3Ik0Muos2D https://t.co/KD95FyJ6tP ...

Live with Carlo now talking the SEC's Regulation Crypto newsNone (@None):Live now for FOMO HOUR talking crypto pump, MRNA solving cancer, PUMP break out, RH chain rebound and then @CarloDAngelo joins to break down the SEC Regulation Crypto newsJump inhttps://t.co/JxqtKUK4Ne ...

Sam, I I say huge news because the market reaction has been huge. So in the pharmaceutical world, is this a really big breakthrough. Oh, hi, Dani.I think the best share price to look at is Merck because that's where you're getting no, let's say, dilution of the of of or or involvement of short covering that's probably going on in the Moderna share price move at the open. So that's giving us a 7%, 9% rise. Right.This is huge for Merck depending on the data. Remember the press release only says that they succ ...

CNBC business news update. Market open. I'm Jessica Edinger and major averages are all higher.Out of the gate, the Dow up 113 points. Merc shares leading it higher. They're up almost 10%.The S&P 500 index up 22 points. The Nasdaq up 19 points. Chipmaker shares mostly in the red.Qualcomm popping one and a half% this morning. Bond yields are lower after what was to some an alarming pop. More on the new Treasury buybacks announced today from CNBC's Andrew Ross Orcin and Becky Quick.The Treasury Department is d ...

Moderna Shares Surge Pre-Market On Landmark Phase 3 Cancer Therapy Results$MRNA stock is set to almost double pre-market after news broke that the company's personalized mRNA cancer vaccine, developed with Merck, met all its objectives in a landmark Phase 3 clinical trial.This is a major milestone for oncology and could trigger a significant liquidity rush, as the equity market prices in the commercialization of personalized genomic medicine.The stock is now available for on-chain investors through @OndoFin ...

JUST IN: Moderna $MRNA surges 130% after cancer vaccine shows signs of preventing melanoma from spreading. https://t.co/YJcx9Bg0g3 ...

Live now for FOMO HOUR talking crypto pump, MRNA solving cancer, PUMP break out, RH chain rebound and then @CarloDAngelo joins to break down the SEC Regulation Crypto newsJump inhttps://t.co/JxqtKUK4Ne ...

Now to a potential breakthrough in the fight against skin cancer. Merck and Moderna said their personalized cancer vaccines helped cut the reoccurrence of melanoma in a late in a large late stage trial. Bloomberg's Madison Muller covers the sector and joins us.I don't know where to start, Madison, whether it's the breakthrough or just the huge move in Moderna shares this morning. This is a really big reaction to the study. Totally.I mean, there are we're winning sort of on multiple fronts here, and I think ...